Prevalence of bisphosphonate therapy in women with breast cancer treated with aromatase inhibitors in Germany .
OBJECTIVE
The aim of this study is to analyze the prevalence of bisphosphonate therapy in women with breast cancer (BC) treated with aromatase inhibitors (AI) in Germany.


METHODS
We included women with BC who started AI therapy between January 2005 and December 2014 (index date) and were followed for a maximum of 24 months. The number of women who received at least one prescription of bisphosphonate during AI therapy was calculated.


RESULTS
A total of 6,959 women with BC who received AI therapy between 2005 and 2014 were analyzed. Of these, only 202 (2.9%) received bisphosphonates.


CONCLUSIONS
The prevalence of bisphosphonate use was low in women with BC treated with AI. .
Louis
L
Jacob
Karel
K
Kostev
Peyman
P
Hadji
D000368:Aged; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D016208:Databases, Factual; D004164:Diphosphonates / Q000627:therapeutic use*; D011307:Drug Prescriptions; D017723:Drug Utilization Review; D005260:Female; D005858:Germany; D019983:Guideline Adherence / Q000639:trends; D006801:Humans; D008875:Middle Aged; D058866:Osteoporotic Fractures / Q000139:chemically induced / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
D047072:Aromatase Inhibitors; D004164:Diphosphonates